Acute coronary syndrom Gensini's score International Index of Erectile dysfunction a b s t r a c t Background/aims: To investigate the prevalence of erectile dysfunction (ED) in patients with coronary artery disease (CAD), its relationship between the severity of ED and the extent of coronary vessel involvement and to register the mean time interval between them. Methods: 240 patients with CAD divided into three age-matched groups: Group 1 (n ¼ 60), ACS with one-vessel disease (1VD); group 2 (n ¼ 60), ACS with 2,3VD; group 3 (n ¼ 60), CSA.
Introduction
Erectile dysfunction (ED) is defined as the consistent inability to reach and maintain an erection satisfactory for sexual activity. 1 This condition is reported to affect 42% of the adults between the ages of 40 and 60 years. 2, 3 The severity of ED is classified as mild to severe, according to the International Index of Erectile Function. 4 Organic ED (i.e. one with an underlying physical etiology) and coronary artery disease (CAD) are closely linked, as they are both consequences of endothelial dysfunction, leading to restrictions in blood flow. 5, 6 Prevalence of ED as high as 75% has been reported in the established CAD patients. 7e12 Atherosclerosis can play a major role in the development of ED both in the general population and in diabetic patients. 13e17 In the diabetic population, the prevalence of silent CAD is particularly high. 18, 19 Evidence to support ED as a predictor of CAD is:
A significant proportion of men with ED exhibit early signs of CAD. Men with pre-existing ED may develop more severe CAD than those without ED. The interval between the onset of ED symptoms and the occurrence of CAD symptoms is estimated at 2e3 years and a cardiovascular event at 3e5 years. There is a common endothelial pathology underlying both ED and CAD. Erectile dysfunction is associated with increased all-cause mortality primarily through its association with CAD mortality.
Erectile dysfunction is associated with significant changes in established cardiovascular risk factors such as fasting lipids, fasting glucose, body mass index (BMI), C-reactive protein (CRP) and homocysteine. 20e23 Men with ED generally exhibit more severe CAD and left ventricular dysfunction than those without ED, 24e26 and the severity of ED may also be correlated with the severity of CAD. 27 It should be noted, however, that penile Doppler testing cannot be reliably used to identify at-risk men because of its average sensitivity and specificity, low positive predictive value and high negative predictive value. 28 In around two-thirds of men, the onset of CAD is preceded by ED (Montorsi et al.) . A number of studies have estimated the interval between the onset of ED symptoms and the occurrence of CAD symptoms as 2e3 years and a cardiovascular event [myocardial infarction (MI) or stroke] as 3e5 years, 29, 30 although longer time frames have been reported. 31 Using Framingham risk scores, the relative risk of developing CAD within 10 years in men with moderate-severe ED has been estimated as 4.9% in those aged 30e39 years, increasing to 21.1% in those aged 60e69 years. 32 This compares with 4.3% and 16.6% in men without ED for the same age groups, i.e. an increase in relative risk of 1.14 and 1.27 respectively. The risk of experiencing a cardiovascular event within a 10-year timeframe is increased by 1.3e1.6 times in men with ED vs. men without ED. 33, 34 2.
Aims and objectives of the study
To investigate the prevalence of ED in patients with CAD and to evaluate the relationship between the severity of ED and the extent of coronary vessel involvement and to register the first symptom and the mean time interval between them. We tested the hypothesis that ED prevalence is related to coronary atherosclerotic burden that in turn is related to the type of clinical presentationdacute coronary syndrome (ACS) vs. chronic coronary syndrome (CCS). As atherosclerosis is a systemic disorder, penile circulation might be involved to a similarly different extent as coronary circulation in ACS vs. CCS patients. If true, ED prevalence should be low in the former and high in the latter. 35, 36 3. Methods 180 patients with CAD divided into three age-matched groups: Group 1 (G1, n ¼ 60), ACS with one-vessel disease (1-VD); Group 2 (G2, n ¼ 60), ACS with 2, 3-VD; Group 3 (G3, n ¼ 60), chronic stable angina, along with Control group (C, n ¼ 60) was composed of patients with suspected CAD who were found to have entirely normal coronary arteries by angiography. International Index of Erectile Function (IIEF) questionnaires were used to assess extent of ED. ED as any value <26 according to the Gensini's scores and according to the IIEF.
Between Dec 2010 and Nov 2011, 1630 patients underwent coronary angiography for both ACS and CCS syndromes at Narayana medical college and Superspeciality hospital, Nellore, Andhra Pradesh. Two-hundred and two patients (12.4%) were found to have angiographically normal coronary arteries. Five-hundred and seventy (35%) were classified as ACS (i.e. first episode of acute ST-elevation myocardial infarction or non-ST elevation myocardial infarction or unstable angina), 37 whereas the remaining patients were classified as CCS (defined as clinical and non-invasive evidence of stable myocardial ischemia lasting >2 months).
We have excluded:
1. Patients with previous percutaneous or surgical myocardial revascularization procedures. 2. Patients with diseases that could alter sexual activity, such as liver cirrhosis, renal failure, thyroid disease (hypo-and hyperthyroidism on replacement treatment), major depression on long-term pharmacological treatment, and spinal cord injuries, and those with previous pelvic, penile, urethral, or prostate trauma or surgery. 3. Patients with primary erectile dysfunction were excluded.
All patients underwent complete routine laboratory tests, included lipid profile, fasting glucose, and total and freeplasma testosterone levels. Diagnostic coronary angiography was carried out in all patients by the standard technique. If required, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery was carried out during the hospital stay. Risk factors (when not previously known) were defined according to the ESC/ACC/AHA guidelines as follows 38 hypertension as blood pressure >140/ 90 mmHg in three consecutive readings, at rest; hypercholesterolemia as total cholesterol level >200 mg/dL and/or LDL cholesterol level >130 mg/dL, diabetes as fasting glucose level >126 mg/dL; obesity as body mass index (BMI) >30 kg/m 2 ; and family history of CAD as parents with CAD at age <55 (father) or <65 (mother).
Ankle-brachial index was taken as an accurate and reliable marker of generalized atherosclerosis. It was calculated by dividing the ankle systolic pressure by the brachial pressure (both measurements taken by cuff manometers). The lower of
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IIEF-EFD questionnaire for ED (questions 1e5 and 15) (1) Q: how often were you able to get an erection during sexual activity? A: no sexual activity (0), almost never/never (1), a few times (much less than half of the time) (2), sometimes (about half of the time) (3), most times (much more than half the time) (4), almost always/always (5). (2) Q: when you had an erection with sexual stimulation, how often were your erections hard enough for penetration? A: no sexual activity (0), almost never/never (1), a few times (much less than half of the time) (2) , sometimes (about half of the time) (3), most times (much more than half the time) (4), almost always/always (5 
Quantitative coronary angiography
Coronary angiography analysis was performed by the cardiologist who is unaware of the patient's ED. IIEF-EFD questionnaire, using ARTREK Quantum IC (Image Comm. System Inc, Sunnyvale, CA, USA). 39 The outer diameter of the contrast-filled catheter was used for calibration. The lesions were analyzed in multiple projections, and reference vessel diameter, minimal lumen diameter, and percent diameter stenosis were measured from the 'worst' angiographic view. Significant angiographic narrowing was defined as >50% diameter stenosis involving either one major epicardial vessel at any site or any collaterals with >0.3 mm diameter. Patients were classified as having 1-VD, 2-VD, or 3-VD, if they had a single lesion in 1, 2, or 3 coronary vessels.
Gensini's score
The method assigns a different severity score depending on the degree of stenosis, its location (proximal, middle or distal tract) along the target vessel and the type of coronary vessel involved (LAD, LCX or RCA) ( Fig. 1 ). 40 
Erectile function evaluation
Erectile function was evaluated by IIEF-EFD, a validated 15-item self-administered questionnaire. 41 Erectile function is specifically addressed by six questions that form the so called 'erectile function domain' of the questionnaire. Each question is scored 0 to 5. ED is defined as any value <26. In the case of ED, patient was asked to answer the following question: 'Did ED symptoms come before CAD symptoms?' If yes,'how long before? (Months)'. IIEF questionnaire was administered to patients after a mean time interval of 3 [2e5] days since the admission to the hospital.
Statistical analysis
The relationship among ED prevalence, clinical presentation, and extension of CAD was analyzed by multivariable logistic regression adjusting for the following covariates: age; diabetes; hypertension; hypercholesterolemia; family history of CAD; smoking; BMI. Adjusted odds ratios (OR) and 95% CI were estimated. The area under the ROC curve was used as a measure of prediction ability. Data are presented as 
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Results
One hundred and eighty patients with angiographically documented CAD were registered. Clinical characteristics of study population are reported in (Table 1 ). There was no difference in age between groups. Risk factors were uniformly distributed between groups, except for smoking and diabetes that were significantly more frequent in G2 and G3 when compared with G1, respectively. Noteworthy, almost 50% of patients in each group had >3 risk factors. Overall ED prevalence was 47%. When separately considered, ED prevalence was 24%, 56%, and 64% in G1, G2, and G3, respectively (p < 0.0001 for G1 vs. G2 and G1 vs. G3; p < 0.45 for G2 vs. G3). ED prevalence in Controls was 22%. ED prevalence was lower in G1 vs. G3 (24 vs. 64%, p<0.00001) as a result of less atherosclerotic burden as expressed by Gensini's score [2 vs. 40, p<0.0001] Controls had ED rate values similar to G1 (24%) ( Table 2 ). Corresponding IIEF-EFD scores were (median and inter quartile range): 26 (24e28), 24 (18e29), and 27 (26e29) in G1, G2, and G3, respectively (p < 0.0004 for G1 vs. G2, P < 0.0001 for G1 vs. G3, and p¼0.48 G2 vs. G3) and 23 (20e26) in controls. Extent of coronary atherosclerosis as assessed by modified Gensini's score was significantly different within each group and between each group and controls. Systemic atherosclerosis, as reflected by the ankle-brachial index, was greater in G3 when compared with G1 (0.80 AE 0.3) vs. 092 AE 0.10, p<0.0001. Severe ED (a score<10) was present in 35/135 (26%) of the CAD patient population and was significantly more frequent in 2, 3-VD when compared with 1-VD (31 vs. 12.5%, p<0.01).
Erectile dysfunction prevalence and IIEF-EFD score according to the extent of coronary atherosclerosis. IIEF-EFD score was significantly lower in multi-vessel disease when compared with single-vessel disease [18 (11.5e23 ) vs. 21 (16e24), p¼0.006]. An inverse relationship was found between modified Gensini's score and IIEF score: R ¼ 20.312, p<0.0001. In G3 patients who complained of ED, symptoms appeared prior to CAD detection in 58/62 (93%) of cases, with a mean time interval of 24 (12e36) months (Fig. 2 ) Time intervals in 1-, 2-, 3-VD patients were 14 months (9e24), 24 months (16e32), and 33 months (21e47), respectively. There was a significant relationship between length of time interval between ED and CAD onset and the number of vessel involved after adjusting for the same covariates as for logistic regression (p¼0.016). Age, multi-vessel coronary involvement, and CCS as clinical presentation were independent predictors of ED. Conversely, in patients with ACS (G1 and G2), we used the number of coronary vessels involved as the dependent variable and ED as a predictor. The presence of ED was associated with a fourfold increase in the risk of having 2-or 3-VD vs.1-VD (Table 3) . Sensitivity, specificity, and positive and negative predictive values of ED vs. multi-vessel disease were 55% (95% CI: 0.35e0.55), 78% (95% CI: 0.68e0.85), 71% (95% CI: 0.59e0.81), and 63% (95% CI: 0.53e0.71), respectively. The area under the ROC curve was 0.663 (95% CI: 0.596e0.725). 
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Discussion A significant proportion of men with ED exhibit early signs of CAD, and this group may develop more severe CAD than men without ED. Prevalence of ED differs across subsets of patients with CAD and is related to extent of CAD. In group I, ED prevalence was 24%. This value was similar to that obtained in age-matched controls with normal coronary arteries. 15 Thus, most patients with ACS and 1-VD do not complain of ED as result of an overall low coronary and penile atherosclerotic burden.
The finding that patients with CCS and 1-VD had higher ED rate (65 vs. 22%, p < 0.0001) when compared with patients with ACS and 1-VD, confirms the role of different pathophysiological background and related atherosclerotic burden at work in CCS ( Fig. 3) . Infact, multivariate analysis showed that patients with CCS presentation had a 2.3-fold increase in relative risk of ED when compared with those with ACS, independently of other conventional risk factors. The lower ankle-brachial index (0.98 þ 0.10 vs.0.80 AE 0.28, p < 0.0001), an accurate and reliable marker of generalized atherosclerosis, supported a more advanced vascular involvement in CCS. The time interval between the onset of ED symptoms and the occurrence of CAD symptoms and cardiovascular events is estimated at 2e3 years and 3e5 years, respectively; this interval allows for risk factor reduction.
According to this finding, we evaluated whether ED may predict coronary artery involvement in ACS. Interestingly enough, this suggests that the IIEF questionnaire may be a useful 'bedside' test to predict the extension of CAD in ACS: according to positive predictive value seven out of 10 patients with ED turned out to have angiographic multivessel disease.
ED-coronary atherosclerosis' relationship by assessing ED rate according to CAD extension is being evaluated in this study. Interesting enough, having 2-or 3-VD did not significantly increased ED prevalence as compared to 1-VD in both ACS and CCS patients with similar age (Fig. 2) suggesting ED as a sort of 'on-off' phenomenon that we hypothesized takes place when 0.50% angiographic obstruction of at least one major coronary vessel occurs. If true, having 2-or 3-VD would not add to ED prevalence. Almost 30% of patients with proved CAD did not complain of ED. Age may be an explanation. We found age to be independent predictor of ED in the whole study patient population, with a 10% per patient increase in the yearly relative risk of ED. ED significantly increased over time being 30% under 50 years and close to 100% over 60 years of age. At any age ED rate was similar regardless extent of CAD, confirming the 'on-off' phenomenon.
We found that severe ED (a score<10) was more frequent in patients with multi-vessel as compared to single-vessel disease (31 vs. 12.5%, p < 0.01). Moreover, IIEF-EFD score was significantly lower in the former than in the latter group and significant inverse relationship between IIEF-EFD and modified Gensini's score were found indicating more severe ED in patients with more diffuse coronary artery involvement. Thus, severe ED in patients with stable CAD should raise questions about multi-vessel coronary involvement.
Conclusion
In the present study, ED prevalence was 24%. ED rate of control group was similar to that found in general population with no heart disease. Patients with CCS presentation had a 2.3fold increase in relative risk of ED when compared with those with ACS. This suggests that the IIEF questionnaire may be a useful 'bedside' test to predict the extension of CAD. Severe ED (a score<10) was more frequent in patients with multi-vessel as compared to single-vessel disease 0.83% of patients with CCS reported ED symptoms before angina pectoris onset, with a mean interval of 22 months heart disease.
The key findings of this study are (1) ED rate significantly differs across patients with established CAD according to coronary clinical presentation and atherosclerosis burden: it is low in ACS and 1-VD and high in CCS. (2) ED severity but not 
R E T R A C T E D
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 1 8 0 e1 8 6 ED prevalence is related to extent of CAD. (3) ED symptoms come prior to CAD symptoms in virtually all patients with a mean time-interval of 3 years. (4) All men with ED should undergo a thorough medical assessment, including testosterone, fasting lipids, fasting glucose and blood pressure measurement. (5) Following assessment, patients should be stratified according to the risk of future cardiovascular events. (6) Those at high risk of cardiovascular disease should be evaluated by stress testing with selective use of computed tomography (CT) or coronary angiography. (7) Improvement in cardiovascular risk factors such as weight loss and increased physical activity has been reported to improve erectile function. (8) In men with ED, hypertension, diabetes and hyperlipidemia should be treated aggressively, bearing in mind the potential side effects. (9) Management of ED is secondary to stabilizing cardiovascular function, and controlling cardiovascular symptoms and exercise tolerance should be established prior to initiation of ED therapy. (10) Clinical evidence supports the use of phosphodiesterase 5 (PDE5) inhibitors as first-line therapy in men with CAD and comorbid ED and those with diabetes and ED. (11) Review of cardiovascular status and response to ED therapy should be performed at regular intervals.
